{"created":"2023-06-19T07:26:14.430499+00:00","id":14599,"links":{},"metadata":{"_buckets":{"deposit":"19ef594c-7b4b-495b-b946-1cc91278b40e"},"_deposit":{"created_by":146,"id":"14599","owners":[146],"pid":{"revision_id":0,"type":"depid","value":"14599"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00014599","sets":["212:261:309"]},"author_link":["35129","35133","35137","35127","35134","35128","35131","35130","35140","35132","35136","35135","35139","35138"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"205031212097417","bibliographicVolumeNumber":"8","bibliographic_titles":[{},{"bibliographic_title":"SAGE Open Medicine","bibliographic_titleLang":"en"}]}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis","subitem_title_language":"en"}]},"item_type_id":"3","owner":"146","path":["309"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-03-09"},"publish_date":"2022-03-09","publish_status":"0","recid":"14599","relation_version_is_last":true,"title":["Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis"],"weko_creator_id":"146","weko_shared_id":-1},"updated":"2023-06-19T07:41:25.181891+00:00"}